Israel Englander Atossa Therapeutics, Inc. Transaction History

Millennium Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.03 - $2.1 $1.03 Million - $2.1 Million	-1,001,085 Reduced 98.95%	10,662 $12,000
Q1 2024 May 15, 2024	BUY	$0.8 - $1.89 $771,580 - $1.82 Million	964,476 Added 2040.31%	1,011,747 $1.82 Million
Q4 2023 Feb 14, 2024	SELL	$0.63 - $0.98 $169,554 - $263,751	-269,134 Reduced 85.06%	47,271 $41,000
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.28 $88,513 - $188,829	-147,523 Reduced 31.8%	316,405 $398,000
Q1 2023 May 15, 2023	SELL	$0.59 - $0.91 $58,787 - $90,671	-99,639 Reduced 17.68%	463,928 $336,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.01 $53,095 - $107,252	-106,191 Reduced 15.86%	563,567 $298,000
Q3 2022 Nov 14, 2022	SELL	$0.82 - $1.14 $709,090 - $985,808	-864,744 Reduced 56.35%	669,758 $558,000

26.5M

466K

91.8K

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $130M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.